IL170888A - Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol and use thereof in the preparation of medicaments - Google Patents

Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol and use thereof in the preparation of medicaments

Info

Publication number
IL170888A
IL170888A IL170888A IL17088805A IL170888A IL 170888 A IL170888 A IL 170888A IL 170888 A IL170888 A IL 170888A IL 17088805 A IL17088805 A IL 17088805A IL 170888 A IL170888 A IL 170888A
Authority
IL
Israel
Prior art keywords
composition according
receptor agonist
mannitol
composition
sugar alcohol
Prior art date
Application number
IL170888A
Other languages
English (en)
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL170888(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
Publication of IL170888A publication Critical patent/IL170888A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL170888A 2003-04-08 2005-09-15 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol and use thereof in the preparation of medicaments IL170888A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (1)

Publication Number Publication Date
IL170888A true IL170888A (en) 2010-06-16

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
IL170888A IL170888A (en) 2003-04-08 2005-09-15 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol and use thereof in the preparation of medicaments
IL197578A IL197578A (en) 2003-04-08 2009-03-12 Solid pharmaceutical preparations suitable for oral administration containing a p1s receptor agonist and sugar alcohol
IL242037A IL242037A0 (en) 2003-04-08 2015-10-12 Solid pharmaceutical preparations consisting of a sip receptor agonist and a sugar alcohol

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL197578A IL197578A (en) 2003-04-08 2009-03-12 Solid pharmaceutical preparations suitable for oral administration containing a p1s receptor agonist and sugar alcohol
IL242037A IL242037A0 (en) 2003-04-08 2015-10-12 Solid pharmaceutical preparations consisting of a sip receptor agonist and a sugar alcohol

Country Status (41)

Country Link
US (11) US20060275357A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (5) EP2769713A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP5495467B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR20110005320A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101797241B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR043987A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (3) AT501681B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2004228929B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (2) BE1015972A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0409250B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2707750A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (2) CL2004000745A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1110260T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (4) DE202004021680U1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2316431T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP056090A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2228282B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2854073B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2400318B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR1005052B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (3) HRP20100600A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE028247T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL170888A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (2) IS2682B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) ITMI20040682A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91867I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27729A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05010860A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY141249A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO329332B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (3) NZ592339A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (5) PE20130200A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2316431T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1613288E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (5) RU2358716C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG175449A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1613288T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN05256A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI332847B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004089341A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200507394B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
DE602006018629D1 (de) * 2005-09-09 2011-01-13 Novartis Ag Behandlung von autoimmunkrankheiten
PT1948678E (pt) 2005-11-09 2013-07-16 Onyx Therapeutics Inc Compostos para inibição de enzimas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ603303A (en) 2006-06-19 2014-05-30 Onyx Therapeutics Inc Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2007302296A1 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
PL2140867T5 (pl) 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Kompozycja farmaceutyczna
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
AU2008310846C1 (en) * 2007-10-12 2022-10-06 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
EP2299982B1 (de) * 2008-06-20 2018-04-04 Merck Patent GmbH Direkt verpressbare und schnell zerfallende tablettenmatirx
DK2334202T3 (da) * 2008-09-04 2012-03-05 Cargill Inc Tablettering af erythritol
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
WO2010055028A2 (en) * 2008-11-11 2010-05-20 Novartis Ag Organic compounds
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010147169A1 (ja) * 2009-06-18 2010-12-23 第一三共株式会社 溶出性の改善された医薬組成物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
WO2011109355A1 (en) 2010-03-01 2011-09-09 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102791271B (zh) 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
CA2804262C (en) 2010-07-02 2016-04-05 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
DK2665471T3 (en) 2011-01-19 2018-03-19 Pathologica Llc ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
EP2742941B1 (en) 2011-08-10 2018-04-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
US9629834B2 (en) * 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4284348A2 (en) * 2021-01-28 2023-12-06 Priothera SAS Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
AU705320B2 (en) 1995-12-28 1999-05-20 Welfide Corporation 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP2030614A1 (en) * 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
NZ500713A (en) * 1997-04-04 2000-07-28 Yoshitomi Pharmaceutical 2-aminopropane-1,3-diol compounds and medicinal use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
HUP0301688A3 (en) 2000-07-13 2006-05-29 Sankyo Co Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
EP1315735A4 (en) * 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
BR0208365A (pt) 2001-03-26 2004-03-09 Novartis Ag Derivados de 2-amino-propanol
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
ES2292809T3 (es) 2001-09-27 2008-03-16 Kyorin Pharmaceutical Co., Ltd. Derivado de sulfuro de diarilo, sal de adicion del mismo, y agente inmunosupresor.
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
JP2005519915A (ja) 2002-01-18 2005-07-07 セレテック・リミテッド・ライアビリティ・カンパニー Ｅｄｇ受容体に関連する症状の処置方法
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
DE602005027074D1 (de) * 2004-07-16 2011-05-05 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen

Also Published As

Publication number Publication date
NO2011016I2 (no) 2012-08-27
KR101367574B1 (ko) 2014-02-25
HK1155647A1 (en) 2012-05-25
AR043987A1 (es) 2005-08-17
ES2556947T3 (es) 2016-01-21
US20140255497A1 (en) 2014-09-11
KR20110005320A (ko) 2011-01-17
ES2228282A1 (es) 2005-04-01
ITMI20040682A1 (it) 2004-07-06
MXPA05010860A (es) 2006-05-25
AR078782A2 (es) 2011-11-30
GB0407819D0 (en) 2004-05-12
US8324283B2 (en) 2012-12-04
RU2475237C2 (ru) 2013-02-20
CY1117071T1 (el) 2017-04-05
HRP20100600A2 (hr) 2011-03-31
AU2004228929A1 (en) 2004-10-21
DE202004021680U1 (de) 2010-04-22
BRPI0409250B1 (pt) 2017-07-11
NO335120B1 (no) 2014-09-22
FR2854073A1 (fr) 2004-10-29
GB2400318B (en) 2005-08-10
IS8885A (is) 2010-02-25
US20090203798A1 (en) 2009-08-13
CA2707750A1 (en) 2004-10-21
DE122011100047I1 (de) 2011-12-15
EP2008650A3 (en) 2011-04-27
IS8114A (is) 2005-11-01
MY141249A (en) 2010-03-31
PE20090743A1 (es) 2009-07-17
CA2521325A1 (en) 2004-10-21
ECSP056090A (es) 2006-03-01
HRP20100601A2 (hr) 2011-03-31
HK1091114A1 (en) 2007-01-12
ATE414508T1 (de) 2008-12-15
HUE028247T2 (en) 2016-12-28
PE20050396A1 (es) 2005-07-05
US20170290787A1 (en) 2017-10-12
NO20055231D0 (no) 2005-11-07
EP2769713A1 (en) 2014-08-27
RU2358716C2 (ru) 2009-06-20
AT501681B1 (de) 2012-04-15
US20200237690A1 (en) 2020-07-30
JP2004307506A (ja) 2004-11-04
GB2400318A (en) 2004-10-13
DK1613288T3 (da) 2009-03-23
JP2011006461A (ja) 2011-01-13
KR20120101148A (ko) 2012-09-12
GR20040100121A (el) 2004-12-17
SI1613288T1 (sl) 2009-04-30
AR078781A2 (es) 2011-11-30
JP5495467B2 (ja) 2014-05-21
CY2011013I1 (el) 2014-04-09
AU2004228929B2 (en) 2008-02-07
SG175449A1 (en) 2011-11-28
TW200503784A (en) 2005-02-01
HRP20100601B1 (hr) 2016-12-02
NO20131287L (no) 2006-01-09
DK2316431T3 (en) 2016-01-11
RU2010146697A (ru) 2012-05-27
FR11C0036I1 (fr) 2011-10-14
US20080311188A1 (en) 2008-12-18
LU91867I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-03
JP2013177404A (ja) 2013-09-09
IL197578A0 (en) 2011-07-31
NO20100250L (no) 2006-01-09
IS2682B (is) 2010-10-15
TNSN05256A1 (en) 2007-07-10
TWI332847B (en) 2010-11-11
US20140011885A1 (en) 2014-01-09
ZA200507394B (en) 2007-03-28
CY1110260T1 (el) 2014-04-09
PL1613288T3 (pl) 2009-07-31
US20130108675A1 (en) 2013-05-02
HUS1100016I1 (hu) 2016-08-29
US20110105620A1 (en) 2011-05-05
DE102004016947A1 (de) 2004-10-21
WO2004089341A1 (en) 2004-10-21
CN101797241A (zh) 2010-08-11
CN1767819B (zh) 2010-07-28
RU2005134173A (ru) 2006-09-10
CY2011013I2 (el) 2014-04-09
CA2521325C (en) 2010-09-14
EP1613288B1 (en) 2008-11-19
EP2008650A2 (en) 2008-12-31
AT501681A1 (de) 2006-10-15
CL2004000745A1 (es) 2005-02-11
SI2316431T1 (sl) 2016-04-29
EP2319502A1 (en) 2011-05-11
HRP20050886A2 (en) 2006-11-30
EP1613288A1 (en) 2006-01-11
IE20040246A1 (en) 2004-12-15
CN1767819A (zh) 2006-05-03
ES2320767T3 (es) 2009-05-28
NZ586280A (en) 2011-12-22
LU91867I2 (fr) 2011-11-08
IL242037A0 (en) 2015-11-30
HRP20050886B1 (en) 2011-01-31
RU2012148593A (ru) 2014-05-20
PT1613288E (pt) 2009-02-25
KR20050121712A (ko) 2005-12-27
IL197578A (en) 2015-10-29
NO2011016I1 (no) 2011-09-19
PE20131352A1 (es) 2013-11-14
PE20130200A1 (es) 2013-03-09
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
FR11C0036I2 (fr) 2023-12-29
PE20150676A1 (es) 2015-05-17
FR2854073B1 (fr) 2008-03-14
US20220031609A1 (en) 2022-02-03
AT504853A2 (de) 2008-08-15
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
NO329332B1 (no) 2010-09-27
DE602004017847D1 (de) 2009-01-02
GR1005052B (el) 2005-11-30
RU2475236C2 (ru) 2013-02-20
RU2009105403A (ru) 2010-08-27
NO334116B1 (no) 2013-12-16
CN101797241B (zh) 2013-03-27
JP5543298B2 (ja) 2014-07-09
NZ542622A (en) 2009-01-31
BE2011C030I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
ES2228282B1 (es) 2006-02-16
EP2316431B1 (en) 2015-09-30
US20190175527A1 (en) 2019-06-13
US20060275357A1 (en) 2006-12-07
RU2010147000A (ru) 2012-08-10
BRPI0409250A (pt) 2006-03-28
BRPI0409250B8 (pt) 2022-01-18
MA27729A1 (fr) 2006-01-02
NZ592339A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
EP2316431B1 (en) Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
AU2011205050B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2008200368B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
IE85095B1 (en) Pharmaceutical composition comprising a sphingosine-1 phosphate receptor agonist

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed